Why the study?
Does chemical perivascular renal denervation with alcohol reduce renal norepinephrine concentration and demonstrate safety in preclinical and early clinical models?
Population
Adult swine (n=17) and human patients in a first-in-man feasibility study (n=18)
Comparison
Chemical renal denervation via peri-adventitial… vs Saline sham control in the preclinical model; no…
Design
Preclinical, Blinded measurement of renal parenchymal norepinephrine…
Follow-up
3 months (preclinical), 6 months (first-in-man)
Authors
Loading...
Supports phase 2 trials of alcohol renal denervation; leaves open clinical efficacy and durability in hypertension.
Does chemical perivascular renal denervation with alcohol reduce renal norepinephrine concentration and demonstrate safety in preclinical and early clinical models?
Chemical perivascular renal denervation using micro-doses of alcohol is feasible, safe, and effectively reduces renal norepinephrine in preclinical models, with promising early safety in humans.
Fischell et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: